18:29 , Jun 21, 2018 |  BC Innovations  |  Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms. Post-traumatic stress disorder (PTSD) is...
19:14 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure In vitro and cell culture studies identified a GRK2-inhibiting analog of Paxil paroxetine that could help treat heart failure. Structure-based design, chemical synthesis and in vitro testing of analogs of the selective serotonin...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

MIN-117: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 84 patients with moderate to severe MDD showed that once-daily 0.5 and 2.5 mg oral MIN-117 for 6 weeks improved MADRS total score by magnitudes...
07:00 , Apr 21, 2016 |  BC Innovations  |  Targets & Mechanisms

Structural SERT-ainty

The publication this month of the crystal structure of the serotonin transporter unquestionably marked a technical watershed, and solved long-asked questions about why similar compounds bind the protein differently. Historically, the target revolutionized depression, spawning the...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

MIN-117: Completed Phase IIa enrollment

Minerva completed enrollment of 84 patients in a double-blind, placebo-controlled, European Phase IIa trial comparing 0.5 and 2.5 mg oral MIN-117 daily vs. 20 mg oral paroxetine daily. Minerva has exclusive, ex-Asian rights to the...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

GlaxoSmithKline, Competition and Markets Authority neurology, generics news

CMA imposed L45 million ($64.8 million) in fines for “pay-for-delay” conduct and agreements occurring between 2001-04 during which GlaxoSmithKline paid over L50 million ($72 million) to suppliers of generic versions of the pharma’s antidepressant Seroxat/...
03:39 , Dec 6, 2014 |  BC Extra  |  Company News

GSK staying put with established products

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) dropped its plan to divest a portfolio of U.S. and European established products after evaluating bids from potential buyers. GSK spokesperson Melinda Stubbee declined to provide further details. In July, the...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Company News

GlaxoSmithKline, Dainippon Sumitomo deal

GlaxoSmithKline and Sumitomo terminated their 2012 co-promotion deal for antidepressant Paxil paroxetine CR in Japan, effective at year end. GSK will be solely responsible for providing information on Paxil CR, a once-daily Geomatrix...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

GlaxoSmithKline neurology, pulmonary news

GlaxoSmithKline has agreed to continue its Patient First Program, which reduces financial incentives for sales representatives to engage in deceptive marketing, at least through March 2019, according to a consent judgment from the Superior Court...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Mylan, GlaxoSmithKline neurology news

In Mylan Inc. et al v. SmithKline Beecham Corp. et al, a jury in the U.S. District Court for the District of New Jersey awarded Mylan $106.7 million in damages from GlaxoSmithKline after ruling...